Xenon Pharmaceuticals XENE Proceeds From Offerings Net
Proceeds From Offerings Net at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept xene:ProceedsFromOfferingsNet.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's proceeds from offerings net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's proceeds from offerings net?
- Xenon Pharmaceuticals (XENE) reported proceeds from offerings net of $837.53M in Q1 2026.
- How has Xenon Pharmaceuticals's proceeds from offerings net changed year-over-year?
- Xenon Pharmaceuticals's proceeds from offerings net increased by 2887.1% year-over-year, from $28.04M to $837.53M.
- What is the long-term trend for Xenon Pharmaceuticals's proceeds from offerings net?
- Over 2 years (2023 to 2025), Xenon Pharmaceuticals's proceeds from offerings net has grown at a -43.7% compound annual growth rate (CAGR), from $353.49M to $112.15M.
- What does proceeds from offerings net mean?
- This metric represents the total cash inflows received from the issuance of equity or debt securities, net of issuance costs and underwriting fees. It serves as a primary indicator of the company's ability to raise external capital to fund research, development, and general corporate operations. High levels of proceeds indicate strong investor confidence and access to capital markets.